These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21902534)

  • 1. Translating potential biomarker candidates for schizophrenia and depression to animal models of psychiatric disorders.
    Kluge W; Alsaif M; Guest PC; Schwarz E; Bahn S
    Expert Rev Mol Diagn; 2011 Sep; 11(7):721-33. PubMed ID: 21902534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models relevant to schizophrenia and autism: validity and limitations.
    Tordjman S; Drapier D; Bonnot O; Graignic R; Fortes S; Cohen D; Millet B; Laurent C; Roubertoux PL
    Behav Genet; 2007 Jan; 37(1):61-78. PubMed ID: 17160702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormalities in metabolism and hypothalamic-pituitary-adrenal axis function in schizophrenia.
    Guest PC; Martins-de-Souza D; Vanattou-Saifoudine N; Harris LW; Bahn S
    Int Rev Neurobiol; 2011; 101():145-68. PubMed ID: 22050851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mice selected for high versus low stress reactivity: a new animal model for affective disorders.
    Touma C; Bunck M; Glasl L; Nussbaumer M; Palme R; Stein H; Wolferstätter M; Zeh R; Zimbelmann M; Holsboer F; Landgraf R
    Psychoneuroendocrinology; 2008 Jul; 33(6):839-62. PubMed ID: 18502051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral and molecular biomarkers in translational animal models for neuropsychiatric disorders.
    Sarnyai Z; Alsaif M; Bahn S; Ernst A; Guest PC; Hradetzky E; Kluge W; Stelzhammer V; Wesseling H
    Int Rev Neurobiol; 2011; 101():203-38. PubMed ID: 22050853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases.
    Quinones MP; Kaddurah-Daouk R
    Neurobiol Dis; 2009 Aug; 35(2):165-76. PubMed ID: 19303440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant mouse models of depression: candidate genes and current mouse lines.
    Urani A; Chourbaji S; Gass P
    Neurosci Biobehav Rev; 2005; 29(4-5):805-28. PubMed ID: 15925701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative proteomics for investigating psychiatric disorders.
    Filiou MD; Turck CW; Martins-de-Souza D
    Proteomics Clin Appl; 2011 Feb; 5(1-2):38-49. PubMed ID: 21280236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders.
    Schwarz E; Bahn S
    Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S133-6. PubMed ID: 18193070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of environmental manipulations in genetically targeted animal models of affective disorders.
    Renoir T; Pang TY; Hannan AJ
    Neurobiol Dis; 2013 Sep; 57():12-27. PubMed ID: 22525570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mice with mutations in the HPA-system as models for symptoms of depression.
    Müller MB; Holsboer F
    Biol Psychiatry; 2006 Jun; 59(12):1104-15. PubMed ID: 16581037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dynamic paradigm in psychopathology: "chaos theory", from physics to psychiatry].
    Pezard L; Nandrino JL
    Encephale; 2001; 27(3):260-8. PubMed ID: 11488256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis.
    Gold SM; Irwin MR
    Neurol Clin; 2006 Aug; 24(3):507-19. PubMed ID: 16877121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism.
    Horrobin DF; Bennett CN
    Prostaglandins Leukot Essent Fatty Acids; 1999 Mar; 60(3):141-67. PubMed ID: 10359017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-environment interactions and construct validity in preclinical models of psychiatric disorders.
    Burrows EL; McOmish CE; Hannan AJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(6):1376-82. PubMed ID: 21168465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of genetically altered brain glucocorticoid receptor action on behavior and adrenal axis regulation in mice.
    Howell MP; Muglia LJ
    Front Neuroendocrinol; 2006 Sep; 27(3):275-84. PubMed ID: 16814372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WFSBP Task Force report on biological markers in depression is unduly pessimistic in failing to find diagnostically helpful measures.
    Taylor MA; Fink M
    World J Biol Psychiatry; 2009; 10(3):252-3; author reply 254. PubMed ID: 19629859
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prevalence of depressive disorders in children and adolescents attending primary care. A survey with the Aquitaine Sentinelle Network].
    Mathet F; Martin-Guehl C; Maurice-Tison S; Bouvard MP
    Encephale; 2003; 29(5):391-400. PubMed ID: 14615688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoid antagonists in neuropsychiatric [corrected] disorders.
    Schatzberg AF; Lindley S
    Eur J Pharmacol; 2008 Apr; 583(2-3):358-64. PubMed ID: 18339372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BDNF in schizophrenia, depression and corresponding animal models.
    Angelucci F; Brenè S; Mathé AA
    Mol Psychiatry; 2005 Apr; 10(4):345-52. PubMed ID: 15655562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.